Maravai LifeSciences Holdings, Inc.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $69.4M | $64.2M | $74.1M | $66.9M | $68.9M | $79.0M | $204.7M | $191.3M |
| Cost of Revenue | $38.6M | $38.3M | $35.1M | $36.7M | $43.3M | $33.7M | $53.3M | $38.2M |
| Gross Profit | $30.8M | $25.8M | $39.0M | $30.2M | $25.6M | $45.3M | $151.5M | $153.1M |
| Gross Margin | 44.4% | 40.3% | 52.6% | 45.1% | 37.2% | 57.4% | 74.0% | 80.0% |
| Operating Expenses | ||||||||
| Research & Development | $4.9M | $5.0M | $4.6M | $4.3M | $4.2M | $4.1M | $5.0M | $5.4M |
| SG&A Expense | $40.6M | $40.9M | $38.5M | $38.9M | $35.4M | $38.7M | $37.2M | $30.8M |
| Operating Income | $-13.4M | $-18.9M | $-7.2M | $-15.4M | $-11.6M | $2.5M | $109.2M | $116.9M |
| Operating Margin | -19.4% | -29.4% | -9.6% | -23.1% | -16.9% | 3.2% | 53.4% | 61.1% |
| Interest Expense | $11.9M | $10.9M | $15.4M | $11.6M | $7.0M | $11.8M | $10.2M | $3.1M |
| Pretax Income | $-20.9M | $-22.4M | $656.2M | $-20.6M | $-13.4M | $-4.5M | $95.9M | $113.8M |
| Income Tax Expense | $-2.4M | $271.0K | $766.2M | $-5.5M | $-1.4M | $-3.2M | $8.4M | $14.1M |
| Net Income | $-9.8M | $-12.1M | $-106.0M | $-6.5M | $-6.5M | $-67.0K | $37.6M | $44.5M |
| Net Margin | -14.1% | -18.8% | -142.9% | -9.7% | -9.5% | -0.1% | 18.4% | 23.3% |
| EPS (Basic) | $-0.07 | $-0.09 | $-0.80 | $-0.05 | $-0.05 | $0.00 | $0.28 | $0.34 |
| EPS (Diluted) | $-0.07 | $-0.09 | $-0.80 | $-0.05 | $-0.05 | $0.00 | $0.30 | $0.34 |
| Shares Outstanding (Basic) | 135.8M | 132.3M | 131.9M | 131.9M | 131.9M | 131.7M | 131.5M | 131.5M |
| Shares Outstanding (Diluted) | 135.8M | 132.3M | 131.9M | 131.9M | 131.9M | 131.7M | 255.3M | 131.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |